TECNO launches an industry-first CMF technology that combines ultra-fine optical fibers with mini-LED lights into smartphone battery covers
HONG KONG, Jan. 10, 2025 /PRNewswire/ -- Innovative technology brand TECNO unveiled its first breakthrough of the year—Starry Optical Fiber Technology—during CES 2025. This industry-first breakthrough intricately combines ultra-fine optical fibers with mini-LED lights, seamlessly integrating them into the battery cover of smartphones. It underscores TECNO's advancements in CMF (Color, Material, Finish) technology and marks a significant leap forward in the development of optical fiber materials for stylish design.
The Starry Optical Fiber Technology transforms the phone's aesthetics, weaving each optical fiber together into a breathtaking light display that shimmers like a galaxy across the back cover. This pioneering technology holds the potential to support applications across a range of devices, including smartphones and tablets.
Redefining Smartphone Design: TECNO's Leap Forward in Aesthetic Innovation
The Starry Optical Fiber battery cover is the world's first to integrate ultra-fine optical fibers and LED lights in a smartphone back cover, crafted through over 30 meticulous manufacturing processes. It incorporates 150 ultra-thin optical fibers, each measuring just 0.125mm in diameter, skillfully threaded through 36 micro-holes with a mere 0.7mm diameter. These fibers are securely fixed using precise UV adhesive, forming a woven, fabric-like structure that adds both durability and visual sophistication. Additionally, 108 mini-LED lights controlled by matrix based smart system are embedded within the battery cover, complementing the optical fibers to produce a stunning luminescent effect.
Despite its dazzling visual effects, the Starry Optical Fiber Technology emphasizes energy efficiency. Both the optical fibers and LED lights are designed for efficient power consumption without compromising on performance, ensuring the phone's battery life remains robust. Furthermore, the unique layout of the fibers and LEDs are configured to maintain heat dissipation, allowing the PHANTOM V Flip2 5G to remain cool and perform efficiently even during prolonged use.
A Fashionable Experience: Four Unique Luminous Modes for Ultimate Immersion
The Starry Optical Fiber Technology is showcased on the PHANTOM V Flip2 5G, TECNO's latest flagship foldable smartphone. This device epitomizes the perfect blend of trendsetting aesthetics and AI-powered technology. Featuring a 3.64-inch ThruPool cover screen and a slightly curved main body, the phone delivers an immersive experience elevated by the Starry Optical Fiber Technology.
TECNO envisions its products not just as tools for efficiency but as personalized expressions of mood and individuality. With four distinct luminous modes: Tidal Waves, Rosy Sunset, Weekend Dusk, and Aurora, each mode has been meticulously designed to combine captivating lighting effects with dynamic soundscapes.
Leading the Industry: Breaking Boundaries in Material Science
Guided by its brand promise of merging innovative technology with modern stylish design, TECNO continues to redefine the smartphone experience. Starry Optical Fiber Technology exemplifies this ethos, blending artistic expression with cutting-edge functionality. Committed to pushing the boundaries of technology innovation, TECNO consistently introduces groundbreaking advancements in material science, aiming to deliver even more transformative technologies that inspire and empower users worldwide.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
TECNO Debuts Groundbreaking Starry Optical Fiber Technology during CES 2025
SEOUL, South Korea, Jan. 10, 2025 /PRNewswire/ -- SN BioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of SNB-101 as an orphan drug for small cell lung cancer in 2023 and its Fast Track designation in 2024. With this latest clearance, SNB-101 is rapidly advancing toward early commercialization in the U.S. market. SN BioScience expects to initiate the clinical trials in Q2, 2025.
Validated for ES-SCLC, SNB-101 Eyes 2028 U.S. Market Launch
SN BioScience has revealed details of its Phase 1b/2 clinical trial for SNB-101, targeting patients diagnosed with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The trial will concentrate on dose escalation and optimization to improve both efficacy and safety. Approximately 55 patients will be enrolled, with a focus on reflecting the racial diversity of the U.S. population. Furthermore, the study, aimed at supporting Phase 2 clearance in Europe, will be conducted across South Korea, the U.S., and Europe. Efficacy, safety, and pharmacokinetics will serve as the primary endpoints. Following the dose optimization phase, the company plans to assess SNB-101's efficacy and safety in approximately 100 patients through a single-arm, single-dose, open-label monotherapy study. If the results are positive, SN BioScience targets early U.S. commercialization, with market entry expected as early as 2028.
Small cell lung cancer (SCLC), representing 12-15% of all lung cancer cases, is an aggressive disease with a poor prognosis. Around 70% of patients are diagnosed at an extensive stage, where the cancer has already spread, resulting in a five-year survival rate of less than 7%. Despite these challenging statistics, the SCLC treatment market is expected to grow at a compound annual growth rate (CAGR) of 7-10% from 2023 to 2030, according to Evaluate Pharma, highlighting the urgent need for more effective therapies. In this context, SNB-101 emerges as a highly promising treatment option, offering the potential to significantly improve patient outcomes.
SN BioScience aims to establish its treatment as a second- or third-line option for patients resistant to existing therapies. Ultimately, the company seeks to position the therapy as a first- or second-line standard treatment, potentially in combination with immuno-oncology agents.
About SN BioScience Inc.
Founded in May 2017, SN BioScience is a biotech company specializing in drug delivery systems for cancer therapies. Based in the 2nd Pangyo Techno Valley in Seongnam-si, Gyeonggi-do, Korea, the company was established by experts in pharmaceutical R&D, world-class bio-polymer researchers, and clinical professionals. Since its inception, SN BioScience has focused on the commercialization of innovative technologies, particularly in the development of nanoliposomes and nanoparticle drug carriers, supported by advanced pharmacometrics and pharmacokinetics.
SNB-101
SNB-101 is an innovative anticancer drug, marking the world's first nanoparticle formulation of SN-38, the active metabolite of irinotecan. Utilizing SN BioScience's dual nano-micelle delivery system, SNB-101 overcomes the drug resistance and safety issues seen with traditional treatments. The drug has already been highlighted for its use in drug-antibody conjugates (ADCs) such as Enhertu® and Trodelvy®. Preclinical studies suggest that SNB-101 may also be effective against lung, pancreatic, and stomach cancers, expanding its potential applications in oncology.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
